Standout Papers

Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated ... 2017 2026 2020 2023 291
  1. Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials (2017)
    Stanley Cohen, Yoshiya Tanaka et al. Annals of the Rheumatic Diseases

Citation Impact

2 from Science/Nature 76 standout
Sub-graph 1 of 19

Citing Papers

JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma
2024 StandoutScience
Persistent physical symptoms: definition, genesis, and management
2024 Standout
18 intermediate papers

Works of Ryan DeMasi being referenced

Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB/IV trial
2019
THU0185 Tofacitinib, An Oral JAK Inhibitor, in The Treatment of Rheumatoid Arthritis: Safety and Clinical and Radiographic Efficacy in Open-Label, Long-Term Extension Studies over 7 Years
2016
and 9 more

Author Peers

Author Rheumatology Hematology Genetics Oncology Last Decade Papers Cites
Ryan DeMasi 723 376 162 229 30 1.0k
Danhui Weng 22 11 55 480 41 1.5k
Joke Devoldere 4 4 12 12 524
Gene L. LaBerge 11 241
Takashi Dejima 6 6 3 108 25 578
Lisa Küpper 5 1.3k

All Works

Loading papers...

Rankless by CCL
2026